Related Experiment Video

Updated: Apr 24, 2026

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

8.2K

The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer

Trine Zeeberg Iversen1, Mads Hald Andersen, Inge Marie Svane

  • 1Department of Haematology and Oncology, Center for Cancer ImmuneTherapy (CCIT), Herlev Hospital, University of Copenhagen, Herlev, Denmark.

Basic & Clinical Pharmacology & Toxicology
|September 11, 2014
PubMed

Insights

This research explores immune cell changes during cancer treatments for metastatic melanoma and non-small-cell lung cancer. Understanding these immune parameters may help predict patient response to immunotherapy and chemotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Immunotherapy has revolutionized cancer treatment, with approvals for sipuleucel-T, ipilimumab (CTLA-4 inhibitor), and ongoing research into PD-1/PD-L1 inhibitors.
  • Despite advancements, only a subset of patients respond to current immunotherapies, necessitating biomarkers for patient selection.
  • Immune checkpoint inhibitors targeting PD-1 and PD-L1 show promise in metastatic melanoma (MM) and non-small-cell lung cancer (NSCLC).

Purpose of the Study:

  • To investigate changes in immune parameters and correlate them with clinical efficacy in patients with metastatic melanoma receiving chemotherapy (temozolomide) and immunotherapy (interferon-α2b/interleukin-2).
  • To assess the safety, tolerability, and immune response correlation with clinical benefit of an indoleamine 2,3 dioxygenase (IDO) peptide vaccination in patients with non-small-cell lung cancer.

Main Methods:

  • Analysis of immune cell subset frequencies and counts before and after treatment in metastatic melanoma patients.
  • Clinical phase 1 study evaluating a peptide vaccine targeting IDO in non-small-cell lung cancer patients.
  • Correlation of immune parameter changes with clinical benefit and response.

Main Results:

  • Changes in immune cell subsets were analyzed in relation to standard chemo- and immunotherapies for metastatic melanoma.
  • A phase 1 clinical trial assessed the safety and immune correlation of an IDO-targeted peptide vaccine in NSCLC.
  • The study aimed to identify immune correlates of response for both treatment modalities.

Conclusions:

  • Scrutinizing immune parameters during cancer treatment is crucial for improving patient selection for immunotherapies.
  • Further research into immune cell dynamics and novel vaccine targets like IDO may enhance treatment efficacy in MM and NSCLC.
  • This thesis contributes to understanding immune responses in cancer patients undergoing diverse therapeutic interventions.

More Related Videos

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)08:42

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)

Published on: June 27, 2025

2.5K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.3K